Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro
about
Autoantibody-induced internalization of CNS AQP4 water channel and EAAT2 glutamate transporter requires astrocytic Fc receptor.The Role of Peripheral CNS-Directed Antibodies in Promoting Inflammatory CNS Demyelination.Finding NMO.Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system.GRP78 autoantibodies initiate the breakdown of the blood-brain barrier in neuromyelitis optica.Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases.Mechanisms for lesion localization in neuromyelitis optica spectrum disorders.Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD).[Optical coherence tomography in neuromyelitis optica spectrum disorders].2-Chlorohexadecanoic acid induces ER stress and mitochondrial dysfunction in brain microvascular endothelial cells.Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.Cerebral Blood Flow Changes in Multiple Sclerosis and Neuromyelitis Optica and Their Correlations With Clinical Disability.Aquaporin-4 Autoantibodies From Neuromyelitis Optica Spectrum Disorder Patients Induce Complement-Independent Immunopathologies in Mice.Diagnosis and Treatment of NMO Spectrum Disorder and MOG-EncephalomyelitisCSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum DisordersBlood Brain Barrier Permeability Could Be a Biomarker to Predict Severity of Neuromyelitis Optica Spectrum Disorders: A Retrospective Analysis
P2860
Q33737913-607DA593-1A1C-4FDB-94AE-70A409C5A7E0Q38714054-0DFD711E-D12A-489C-B7DB-6E30DB1E1484Q42346102-9AD88DC6-2F61-4585-AEB7-77C62A00C635Q42361527-ACE7B126-6D37-4347-8719-94487BB323B1Q47145475-7C3A7B24-8F05-4120-ADBA-640E1405808BQ47163794-A95B092C-7B72-4AE1-A185-BD356CA11E0BQ49713173-4A756958-7824-45F3-AEC5-6303069C6C25Q50067506-9496A1A4-5136-474E-A42D-04B8C4CCE97DQ50101454-F4AD2191-BDC8-4A04-8B04-F2B7DE8906DFQ50136719-3943FE8F-E811-4B08-9F3D-9E3BF1E518A6Q52668258-63FBF2C9-1581-4EEC-B7E8-E13C36DF5913Q54935884-34B7FB01-989A-4A56-AE27-E18D147C3CFBQ55498468-CEB3438F-7AE8-4FB2-872B-C3CDCC95885EQ58573155-67CA6B24-060A-465A-B282-01C57A24B609Q58698171-EE3923A0-FB5A-482D-ACDA-4F19829842EEQ58797276-3D49561E-6447-4024-B561-9CE23F567911
P2860
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro
@en
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro.
@nl
type
label
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro
@en
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro.
@nl
prefLabel
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro
@en
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro.
@nl
P2093
P2860
P1476
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro
@en
P2093
Anne C Cotleur
Birgit Obermeier
Erin Yamamoto
Fumitaka Shimizu
Richard M Ransohoff
Takashi Kanda
Thomas J Kryzer
Vanda A Lennon
Yasuteru Sano
Yukio Takeshita
P2860
P356
10.1212/NXI.0000000000000311
P577
2016-12-19T00:00:00Z